descartes-08
descartes-08: 4 clinical trials tracked.
descartes-08 evidence translation
What we can confirm
4 tracked trials
What it means
What to watch
Prepared research question
What is verified about descartes-08, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (4)
A Randomized Double-Blind Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of Descartes-08 in Patients With Dermatomyositis and Antisynthetase Syndrome
Primary endpoint: Major improvement of 2016 ACR/EULAR Total Improvement score
Descartes-08 for Children, Adolescents and Young Adults With Childhood-onset Systemic Lupus Erythematosus, ANCA-associated Vasculitis, Juvenile Myasthenia Gravis, and Juvenile Dermatomyositis
Primary endpoint: Maximum tolerated dose in Part 1, type and frequency of treatment related SAE's in Part 2
Descartes-08 for Patients With Systemic Lupus Erythematosus
Primary endpoint: Assess safety and tolerability of Descartes-08 in patients with systemic lupus erythematosus (SLE)
Autologous T-Cells Expressing A Chimeric Antigen Receptor Directed To B-Cell Maturation Antigen (BCMA) In Patients With Generalized Myasthenia Gravis (MG)
Primary endpoint: Proportion of patients with MG Composite improvement of ≥5 points.